86552-55-8Relevant academic research and scientific papers
UV-mediated hydrophosphinylation of unactivated alkenes with phosphinates under batch and flow conditions
Gelat, Fabien,Roger, Maxime,Penverne, Christophe,Mazzad, Ahmed,Rolando, Christian,Chausset-Boissarie, La?titia
, p. 8385 - 8392 (2018)
A UV-mediated hydrophosphinylation of unactivated alkenes with H-phosphinates and hypophosphorous acid under radical free conditions is presented. The reaction affords selectively a large number of structurally diverse organophosphorous compounds in moderate to good yields under mild reaction conditions in the presence of an organic sensitizer as catalyst irradiated by UV-A LEDs. Furthermore, the high yielding hydrophosphinylation in continuous flow is disclosed.
AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
-
Page/Page column 80; 123, (2020/06/10)
The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.
Selective inhibitors of neurotensin degrading enzymes
-
Page/Page column 9, (2008/12/06)
Embodiments of this invention relate to compounds that are selective inhibitors of neurotensin degrading enzymes, to pharmaceutical compositions containing these compounds, to methods for preparing these compounds, methods for preparing novel intermediate
PHOSPHINIC ACID ANALOGS OF GLUTAMATE
-
Page 18-19, (2010/02/07)
Inhibitors of axillary malodour having the formula (I): wherein R has the same meaning as given in the specification.
PHOSPHINIC ACID ANALOGS OF GLUTAMATE
-
Page 16-17, (2010/02/07)
Inhibitors of axillary malodour having the formula[insert here Formula (I)]wherein R has the same meaning as in the specification.
Prodrugs of NAALAdase inhibitors
-
, (2008/06/13)
The present invention relates to prodrugs of NAALADase inhibitors, pharmaceutical compositions comprising the same, and methods of using the same to treat glutamate abnormalities and prostate diseases.
Methods of cancer treatment using naaladase inhibitors
-
, (2008/06/13)
The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel methods of using phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives to inhibit N-Acetylated alpha -Linked Acidic Dipeptidase (NA
Certain dioic acid derivatives useful as NAALADase inhibitors
-
, (2008/06/13)
The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives that inhibit N-Acetylated alpha -Linked Acidic Dipeptidase (NAALADase) enzyme
NAALADase inhibitors
-
, (2008/06/13)
The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives that inhibit N-Acetylated alpha -Linked Acidic Dipeptidase (NAALADase) enzyme
Inhibitors of NAALADase enzyme activity
-
, (2008/06/13)
The present disclosure relates to dipeptidase inhibitors, and more particularly, to novel methods of using phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives to inhibit N-Acetylated alpha -Linked Acidic Dipeptidase (NA
